Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation

被引:95
作者
Joffe, HV [1 ]
Adler, GK [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA
关键词
aldosterone; renin-angiotensin system; inflammation; cardiovascular diseases; receptors; mineralocorticoid;
D O I
10.1007/s10741-005-2346-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aldosterone, the final product of the renin-angiotensin-aldosterone system, is classically viewed as a regulator of renal sodium and potassium handling, blood volume, and blood pressure. Recent studies suggest that aldosterone can cause microvascular damage, vascular inflammation, oxidative stress and endothelial dysfunction. In animal models, aldosterone-mediated vascular injury in the brain, heart, and kidneys leads to stroke, myocardial injury, and proteinuria. These effects may be modified by dietary salt intake; aldosterone-mediated vascular damage is increased in susceptible animals fed a high-salt diet compared to a low-salt diet despite lower plasma aldosterone levels on the high-salt diet. In humans, there is a growing literature supporting the adverse effects of aldosterone in heart failure, hypertension, left ventricular hypertrophy, and renal disease. Aldosterone receptor antagonists are beneficial even in patients on angiotensin converting enzyme inhibitors and attenuate aldosterone-mediated vascular injury by mechanisms that appear to be independent of changes in systolic blood pressure. This review focuses on the adverse effects of aldosterone on the vascular system and describes our current understanding of the underlying mechanisms for this injury.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 40 条
[1]   Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole [J].
Arima, S ;
Kohagura, K ;
Xu, HL ;
Sugawara, A ;
Uruno, A ;
Satoh, F ;
Takeuchi, K ;
Ito, S .
HYPERTENSION, 2004, 43 (02) :352-357
[2]   Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction - Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression [J].
Bauersachs, J ;
Heck, M ;
Fraccarollo, D ;
Hildemann, SK ;
Ertl, G ;
Wehling, M ;
Christ, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :351-358
[3]   Endothelial function: From vascular biology to clinical applications [J].
Behrendt, D ;
Ganz, P .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (10C) :40L-48L
[4]   Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats [J].
Blasi, ER ;
Rocha, R ;
Rudolph, AE ;
Blomme, EAG ;
Polly, ML ;
McMahon, EG .
KIDNEY INTERNATIONAL, 2003, 63 (05) :1791-1800
[5]   Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production [J].
Brown, NJ ;
Kim, KS ;
Chen, YQ ;
Blevins, LS ;
Nadeau, JH ;
Meranze, SG ;
Vaughan, DE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (01) :336-344
[6]  
Burgess E., 2002, American Journal of Hypertension, V15, p23A, DOI 10.1016/S0895-7061(02)02330-0
[7]   Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. [J].
Chrysostomou, A ;
Becker, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :925-926
[8]  
Dzau VJ, 2001, AM J CARDIOL, V88, p1L
[9]   Recent landmark clinical trials: How do they modify the therapeutic paradigm? [J].
Epstein, M .
AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (07) :82S-84S
[10]   Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure [J].
Farquharson, CAJ ;
Struthers, AD .
CIRCULATION, 2000, 101 (06) :594-597